Clearing persistent extracellular antigen of hepatitis B virus: An immunomodulatory strategy to reverse tolerance for an effective therapeutic vaccination

Danming Zhu, Longchao Liu, Dan Yang, Sherry Fu, Yingjie Bian, Zhichen Sun, Junming He, Lishan Su, Liguo Zhang, Hua Peng, Yang Xin Fu

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Development of therapeutic vaccines/strategies to control chronic hepatitis B virus (HBV) infection has been challenging because of HBV-induced tolerance. In this study, we explored strategies for breaking tolerance and restoring the immune response to the HBV surface Ag in tolerant mice. We demonstrated that immune tolerance status is attributed to the level and duration of circulating HBsAg in HBV carrier models. Removal of circulating HBsAg by a monoclonal anti-HBsAg Ab in tolerant mice could gradually reduce tolerance and reestablish B cell and CD4+ T cell responses to subsequent Engerix-B vaccination, producing protective IgG. Furthermore, HBsAg-specific CD8+ T cells induced by the addition of a TLR agonist resulted in clearance of HBV in both serum and liver. Thus, generation of protective immunity can be achieved by clearing extracellular viral Ag with neutralizing Abs followed by vaccination.

Original languageEnglish (US)
Pages (from-to)3079-3087
Number of pages9
JournalJournal of Immunology
Volume196
Issue number7
DOIs
StatePublished - Apr 1 2016

Fingerprint

Hepatitis B virus
Hepatitis B Surface Antigens
Vaccination
Antigens
Immune Tolerance
T-Lymphocytes
Therapeutics
Chronic Hepatitis B
Virus Diseases
Immunity
B-Lymphocytes
Vaccines
Immunoglobulin G
Liver
Serum

ASJC Scopus subject areas

  • Immunology

Cite this

Clearing persistent extracellular antigen of hepatitis B virus : An immunomodulatory strategy to reverse tolerance for an effective therapeutic vaccination. / Zhu, Danming; Liu, Longchao; Yang, Dan; Fu, Sherry; Bian, Yingjie; Sun, Zhichen; He, Junming; Su, Lishan; Zhang, Liguo; Peng, Hua; Fu, Yang Xin.

In: Journal of Immunology, Vol. 196, No. 7, 01.04.2016, p. 3079-3087.

Research output: Contribution to journalArticle

Zhu, Danming ; Liu, Longchao ; Yang, Dan ; Fu, Sherry ; Bian, Yingjie ; Sun, Zhichen ; He, Junming ; Su, Lishan ; Zhang, Liguo ; Peng, Hua ; Fu, Yang Xin. / Clearing persistent extracellular antigen of hepatitis B virus : An immunomodulatory strategy to reverse tolerance for an effective therapeutic vaccination. In: Journal of Immunology. 2016 ; Vol. 196, No. 7. pp. 3079-3087.
@article{0300069c4c5742ae9e66e163551127f7,
title = "Clearing persistent extracellular antigen of hepatitis B virus: An immunomodulatory strategy to reverse tolerance for an effective therapeutic vaccination",
abstract = "Development of therapeutic vaccines/strategies to control chronic hepatitis B virus (HBV) infection has been challenging because of HBV-induced tolerance. In this study, we explored strategies for breaking tolerance and restoring the immune response to the HBV surface Ag in tolerant mice. We demonstrated that immune tolerance status is attributed to the level and duration of circulating HBsAg in HBV carrier models. Removal of circulating HBsAg by a monoclonal anti-HBsAg Ab in tolerant mice could gradually reduce tolerance and reestablish B cell and CD4+ T cell responses to subsequent Engerix-B vaccination, producing protective IgG. Furthermore, HBsAg-specific CD8+ T cells induced by the addition of a TLR agonist resulted in clearance of HBV in both serum and liver. Thus, generation of protective immunity can be achieved by clearing extracellular viral Ag with neutralizing Abs followed by vaccination.",
author = "Danming Zhu and Longchao Liu and Dan Yang and Sherry Fu and Yingjie Bian and Zhichen Sun and Junming He and Lishan Su and Liguo Zhang and Hua Peng and Fu, {Yang Xin}",
year = "2016",
month = "4",
day = "1",
doi = "10.4049/jimmunol.1502061",
language = "English (US)",
volume = "196",
pages = "3079--3087",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "7",

}

TY - JOUR

T1 - Clearing persistent extracellular antigen of hepatitis B virus

T2 - An immunomodulatory strategy to reverse tolerance for an effective therapeutic vaccination

AU - Zhu, Danming

AU - Liu, Longchao

AU - Yang, Dan

AU - Fu, Sherry

AU - Bian, Yingjie

AU - Sun, Zhichen

AU - He, Junming

AU - Su, Lishan

AU - Zhang, Liguo

AU - Peng, Hua

AU - Fu, Yang Xin

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Development of therapeutic vaccines/strategies to control chronic hepatitis B virus (HBV) infection has been challenging because of HBV-induced tolerance. In this study, we explored strategies for breaking tolerance and restoring the immune response to the HBV surface Ag in tolerant mice. We demonstrated that immune tolerance status is attributed to the level and duration of circulating HBsAg in HBV carrier models. Removal of circulating HBsAg by a monoclonal anti-HBsAg Ab in tolerant mice could gradually reduce tolerance and reestablish B cell and CD4+ T cell responses to subsequent Engerix-B vaccination, producing protective IgG. Furthermore, HBsAg-specific CD8+ T cells induced by the addition of a TLR agonist resulted in clearance of HBV in both serum and liver. Thus, generation of protective immunity can be achieved by clearing extracellular viral Ag with neutralizing Abs followed by vaccination.

AB - Development of therapeutic vaccines/strategies to control chronic hepatitis B virus (HBV) infection has been challenging because of HBV-induced tolerance. In this study, we explored strategies for breaking tolerance and restoring the immune response to the HBV surface Ag in tolerant mice. We demonstrated that immune tolerance status is attributed to the level and duration of circulating HBsAg in HBV carrier models. Removal of circulating HBsAg by a monoclonal anti-HBsAg Ab in tolerant mice could gradually reduce tolerance and reestablish B cell and CD4+ T cell responses to subsequent Engerix-B vaccination, producing protective IgG. Furthermore, HBsAg-specific CD8+ T cells induced by the addition of a TLR agonist resulted in clearance of HBV in both serum and liver. Thus, generation of protective immunity can be achieved by clearing extracellular viral Ag with neutralizing Abs followed by vaccination.

UR - http://www.scopus.com/inward/record.url?scp=84962597523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962597523&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1502061

DO - 10.4049/jimmunol.1502061

M3 - Article

C2 - 26936879

AN - SCOPUS:84962597523

VL - 196

SP - 3079

EP - 3087

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 7

ER -